Product Description
APPL-001 are allogenic placental pluripotent cells for the treatment of Crohn's Disease. (Sourced from: https://celularity.com/wp-content/uploads/Celularity-Investor-Presentation-1.7.20.pdf)
Mechanisms of Action: Stem Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Celularity
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Crohn Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|